Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Eduardo Castanon Alvarez"'
Autor:
Capucine Baldini, Nadia Younan, Eduardo Castanon Alvarez, Samy Ammari, Agusti Alentorn, Sarah Dumont, Jean-Sebastien Frenel, Anna-Luisa Di Stefano, Guillaume Louvel, Jean-Marie Michot, Rastislav Bahleda, Sophie Postel-Vinay, Andreea Varga, Aurélien Marabelle, Antoine Hollebecque, Franck Bielle, Khê Hoang-Xuan, Jean-Yves Delattre, Frederic Dhermain, Marc Sanson, Jean-Charles Soria, Ahmed Idbaih, Christophe Massard, Mehdi Touat
Publikováno v:
European Journal of Cancer. 163:98-107
Recent studies showed that patients with glioma can safely participate in early phase clinical trials; however, clinical benefits in this population were limited. We aimed to evaluate the benefit of molecular profiling to guide enrolment in early pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5deb1dc3f0e88cac2481b8dae5ee08d4
https://doi.org/10.1016/j.ejca.2021.11.017
https://doi.org/10.1016/j.ejca.2021.11.017
Autor:
Roberto Martin Huertas, Stéphane Dalle, Juan Martin-Liberal, Sorilla Prey, Caroline Dutriaux, Henry Montaudie, Marisol Quintero, Philippe Saiag, Juan Francisco Rodriguez-Moreno, Enrique de Miguel, Julie Charles, Eva Muñoz Couselo, Alfonso Berrocal, Maria Gonzalez Cao, Elisa Funk-Brentano, Delvys Rodriguez Abreu, Eduardo Castanon Alvarez, Helena Escuin-Ordinas, Javier Sánchez López, Caroline Robert, Ana Arance, María Pilar López Criado, Luis Merino, Pablo Cerezuela-Fuentes, Ivan Marquez Rodas, Sonia Maciá, Marya F. Chaney, Miguel F. Sanmamed
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundIntratumoral immunotherapies are being tested in different solid tumors. They trigger local and systemic responses.1 2 BO-112 is a double stranded RNA nanoplexed with polyethyleneimine (PEI), which mimics a viral infection and mobilizes the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e402ca5ac12d03a7ed527395e7f52c31
https://doaj.org/article/cfa232992c194eb9b490f0ff34e0deec
https://doaj.org/article/cfa232992c194eb9b490f0ff34e0deec
Autor:
Michele Petruzzelli, Sophie Postel-Vinay, Elena Garralda, John D. Powderly, Melissa Lynne Johnson, Eduardo Castanon Alvarez, Christos Kyriakopoulos, Rafael Villanueva, Funda Meric-Bernstam, Cesar Augusto Santa-Maria, Mateusz Opyrchal, John Stone, Frederick Goldberg, Stephen McMorn, Tinnu Sarvotham, Alvin Milner, Helen Angell, Teresa Collins, Christophe Massard, Lillian L. Siu
Publikováno v:
Journal of Clinical Oncology. 40:TPS3166-TPS3166
TPS3166 Background: The forkhead box family transcription factor FOXP3 is essential for T regulatory cells (Tregs) development and immune suppressive function. Tregs are an integral component of the adaptive immune system and contribute to maintainin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20d03a11932d5250a64565f1fda23eb4
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3166
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3166
Autor:
Thierry Andre, Filippo G. De Braud, Begona Jimenez-Rodriguez, Dominique Berton, Giuseppe Curigliano, Tobias Arkenau, Antonio Antón Torres, David Paez, Susan Ellard, Cyril Abdeddaim, Eduardo Castanon Alvarez, Francine Aubin, Tao Duan, Jennifer Taylor Veneris, Eleftherios Zografos, Naureen Starling
Publikováno v:
Journal of Clinical Oncology. 40:201-201
201 Background: Dostarlimab is a programmed death receptor-1 (PD-1) blocking antibody that is approved in the US as a monotherapy in adult patients (pts) with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b8db3e04d3b2edfd6e4a0761e5ec151
https://doi.org/10.1200/jco.2022.40.4_suppl.201
https://doi.org/10.1200/jco.2022.40.4_suppl.201
Autor:
Hyun Cheol Cheol Chung, Zarnie Lwin, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Eduardo Castanon Alvarez, Donna M. Graham, Mark Doherty, Philippe Cassier, Juanita Suzanne Lopez, Bristi Basu, Andrew Eugene Hendifar, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Esma Saada-Bouzid
Publikováno v:
Journal of Clinical Oncology. 39:4030-4030
4030 Background: Lenvatinib, an anti-angiogenic multiple receptor tyrosine kinase inhibitor, in combination with the anti‒PD-1 antibody pembrolizumab, has demonstrated promising antitumor activity with manageable safety in the first- or second-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b6bdee561ddcc162bdc71861ce7300f
https://doi.org/10.1200/jco.2021.39.15_suppl.4030
https://doi.org/10.1200/jco.2021.39.15_suppl.4030
Autor:
Carlos A. Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Juanita Suzanne Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Hyun Cheol Cheol Chung
Publikováno v:
Journal of Clinical Oncology. 39:3564-3564
3564 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient colorectal cancer, both as firs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f10a4651235e2a1fa13a0d027d1dcfba
https://doi.org/10.1200/jco.2021.39.15_suppl.3564
https://doi.org/10.1200/jco.2021.39.15_suppl.3564
Autor:
Carlos Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Helene Senellart, Mark Doherty, Javier García-Corbacho, Juanita Suzanne Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Hyun Cheol Chung
Publikováno v:
Journal of Clinical Oncology. 39:94-94
94 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient colorectal cancer, both as first-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5775c565322b1d8ebbf02995440fd2d9
https://doi.org/10.1200/jco.2021.39.3_suppl.94
https://doi.org/10.1200/jco.2021.39.3_suppl.94
Autor:
Philippe A. Cassier, Hyun Cheol Chung, Esma Saada-Bouzid, Fan Jin, Corinne Maurice-Dror, Sanjeev Gill, Zarnie Lwin, Carlos Gomez-Roca, Kevin Norwood, Donna M. Graham, Andrew Eugene Hendifar, Juanita Lopez, Razi Ghori, Eduardo Castanon Alvarez, Eduardo Yanez, Bristi Basu, Federico Longo, Peter Kubiak, Mark Doherty
Publikováno v:
Journal of Clinical Oncology. 39:230-230
230 Background: Lenvatinib, an anti-angiogenic multiple receptor tyrosine kinase inhibitor, in combination with the anti‒PD-1 antibody pembrolizumab, has demonstrated promising antitumor activity with manageable safety in the first- or second-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f5429d286f03d1a33f90a93260c5531
https://doi.org/10.1200/jco.2021.39.3_suppl.230
https://doi.org/10.1200/jco.2021.39.3_suppl.230
Autor:
Alvaro Sanchez Arraez, Eduardo Castanon Alvarez, L. Resano, Covadonga Vidal, Antonio Gonzalez Martin, Mariano Ponz-Sarvise, Luis Barba
Publikováno v:
Journal of Clinical Oncology. 38:e14094-e14094
e14094 Background: Selection of patients for enrolment in phase I trials is critical. Initial scores (RMS or MDAS) were designed to select patients with higher probability to obtain benefit in a clinical trial, followed by others such as GRIM score a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a250aafa03aeec8883ee170ca88e7a17
https://doi.org/10.1200/jco.2020.38.15_suppl.e14094
https://doi.org/10.1200/jco.2020.38.15_suppl.e14094
Autor:
Vivek Subbiah, Dmitriy Zamarin, Omid Hamid, Igor Feldman, Thomas Marron, Yuling Wu, Inderjit Mehmi, Michael Abadier, Analia Azaro, Anthony El-Khoueiry, Eduardo Castañón Álvarez, Jacky Chow, Praveen Aanur, Khanh Do, Vasudha Sehgal, Sandip P Patel, Benedito Carneiro, Linh Van, Nicholas Durham, Xiaoru Chen, Paula G Fraenkel, Arjun Oberoi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c2b5cd1235c14787ac32086337332951